Merck's 2026 narrative is centered on Keytruda, the world's top-selling cancer drug. The market has treated Merck like a "one-trick pony" due to the looming 2028 "patent cliff," where Keytruda will lose its legal protection and face generic competition. The transformation of the company's portfolio, bolstered by the acquisitions of Verona Pharma and Cidara Therapeutics, is well underway, with momentum building as it continues to execute on its strategy.
Cyborg Score Rationale
Merck reported quarterly revenue of $16.4 billion, up 5% from the same period a year earlier. The company is implementing a $3 billion cost reduction program by end of 2027 while preparing to offset revenue losses from Keytruda's 2028 patent expiration. Strategic acquisitions and portfolio diversification provide growth optionality, though patent cliff remains a key risk.
Top Insights
Keytruda sales reached $8.37 billion in Q4, rising 7% year-over-year, driven by uptake for earlier-stage cancers and strong demand for metastatic cancer treatment.
Newer drug Winrevair, used to treat pulmonary arterial hypertension, recorded $467 million in sales for the quarter, up 133% from the same period a year earlier.
Merck's animal health division posted nearly $1.51 billion in sales, up 8% from the prior year.
Gardasil generated $1.03 billion in quarterly sales, down 34% due to lower demand in China and reduced CDC pediatric vaccine recommendations.
Named Competitors
Keytruda — Checkpoint inhibitor for oncology applications
Opdivo — Competing immunotherapy for cancer
Tecentriq — PD-L1 inhibitor for multiple cancer types
Pharamacuetical Portfolio — Diversified global pharma competitor
Recent Developments
(February 2026) FDA approved Keytruda for platinum-resistant carcinomas expansion
(January 2026) Completed $221.50 per share acquisition of Cidara Therapeutics
(January 2026) Initiated Phase 3 KANDLELIT-007 trial for calderasib plus Keytruda in KRAS G12C-mutant NSCLC
(February 2026) European CHMP recommended expanding Winrevair indication for pulmonary arterial hypertension WHO Functional Class II, III and IV
Open the full interactive Merck & Co., Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.